

Oleksandr Kalyuzhniy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4920313/publications.pdf>

Version: 2024-02-01

20
papers

3,871
citations

430442

18
h-index

794141

19
g-index

20
all docs

20
docs citations

20
times ranked

3862
citing authors

#	ARTICLE	IF	CITATIONS
1	Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors. <i>Science</i> , 2013, 340, 711-716.	6.0	680
2	Proof of principle for epitope-focused vaccine design. <i>Nature</i> , 2014, 507, 201-206.	13.7	451
3	HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. <i>Science</i> , 2016, 351, 1458-1463.	6.0	382
4	Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. <i>Science</i> , 2015, 349, 156-161.	6.0	358
5	HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. <i>Immunity</i> , 2016, 45, 483-496.	6.6	335
6	Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. <i>Immunity</i> , 2018, 48, 133-146.e6.	6.6	274
7	Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. <i>Cell</i> , 2016, 166, 1459-1470.e11.	13.5	230
8	Computational Design of Epitope-Scaffolds Allows Induction of Antibodies Specific for a Poorly Immunogenic HIV Vaccine Epitope. <i>Structure</i> , 2010, 18, 1116-1126.	1.6	203
9	A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. <i>Science</i> , 2019, 366, .	6.0	172
10	Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. <i>Science</i> , 2016, 353, 1557-1560.	6.0	147
11	Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. <i>Nature Communications</i> , 2017, 8, 1655.	5.8	142
12	The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	113
13	Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies. <i>Immunity</i> , 2018, 49, 301-311.e5.	6.6	110
14	Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. <i>PLoS Pathogens</i> , 2016, 12, e1005815.	2.1	104
15	Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design. <i>PLoS Pathogens</i> , 2017, 13, e1006212.	2.1	58
16	B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 22920-22931.	3.3	42
17	Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6849-E6858.	3.3	38
18	Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. <i>PLoS Pathogens</i> , 2018, 14, e1006986.	2.1	28

#	ARTICLE	IF	CITATIONS
19	Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer. Cell Reports, 2022, 38, 110485.	2.9	4
20	Highly Mutated Antibodies Capable of Neutralizing N276-Glycan Deficient HIV after a Single Immunization with an Env Trimer. SSRN Electronic Journal, 0, , .	0.4	0